We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
201
PUT
Invesco QQQ Trust
QQQ
$436B
– –
-550,000
Closed -$29.6M
REGN icon
202
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-130,000
Closed -$63.5M
RLMD icon
203
Relmada Therapeutics
RLMD
$540M
– –
-55,172
Closed -$1.88M
FLNA
204
Filana Therapeutics
FLNA
$42M
– –
-300,000
Closed -$1.23M
SLDB icon
205
CALL
Solid Biosciences
SLDB
$792M
– –
-29,987
Closed -$1.07M
SPY icon
206
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$771B
– –
-250,000
Closed -$64.4M
TLT icon
207
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$42.4B
– –
-400,000
Closed -$66M
TPST icon
208
PUT
Tempest Therapeutics
TPST
$14.3M
– –
-7,199
Closed -$7.41M
XBI icon
209
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-250,000
Closed -$19.4M
CMRX
210
DELISTED
Chimerix, Inc.
CMRX
– –
-208,258
Closed -$300K
BLU
211
DELISTED
BELLUS Health Inc.
BLU
– –
-63,721
Closed -$891K
CCXI
212
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-150,000
Closed -$6.03M
XLRN
213
DELISTED
Acceleron Pharma
XLRN
– –
-239,249
Closed -$23.1M
ALXN
214
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-200,000
Closed -$18M
MYOK
215
CALL
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-113,400
Closed -$5.32M
MNK
216
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-194,322
Closed -$385K
PFNX
217
DELISTED
Pfenex Inc.
PFNX
– –
-64,211
Closed -$566K
PGNX
218
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-130,845
Closed -$497K
5 6 7 8
9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.